BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.94−0.04 (-2.02%)
Close on Nov 17, 2026Market cap $155.54MP/E –Yield –
BridgeBio Oncology Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BridgeBio Oncology Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$151.28M. For fiscal 2025 it was -$113.89M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$113.89M | – |
| FY2024 | Dec 31, 2024 | -$55.03M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.36M | – |
| Q1 FY2026 | Mar 31, 2026 | -$35.92M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$39.34M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.10K | – |
| Q1 FY2024 | Mar 31, 2024 | -$618.00K | – |
See a number that looks wrong?